We only have this paper's title and publication details.
Read it at the sourceRandomized trial evaluates 78-week outcomes of alirocumab in heterozygous familial hypercholesterolaemia, indicating its role in long-term lipid management.
Cinicaltrials.gov (identifiers: NCT01623115; NCT01709500).
No takes yet. Share an insight, caveat, or question.
Kastelein et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: